RAYMOND DEBBANE
CIK 1053890 · last filed 2026-06-04
RAYMOND DEBBANE is a corporate insider who has filed 124 SEC Form 4 insider transactions across 7 companies since 2007. The most recent filing, for LXRX, was dated Jun 4, 2026. Across all open-market trades the lifetime net is −$72.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $506.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$506.30M
7
124
-$72.39M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LXRX | Director | 3,533,960 | $1.92 | $6.79M | $5.43M | 35 | 2026-06-04 |
| SRRK | 10%+ Owner | 11,051,166 | $44.18 | $488.24M | -$78.79M | 1 | 2024-11-27 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | 10%+ Owner | 7,146,381 | $15.70 | $112.20M | -$355.5K | 1 | 2024-08-05 |
| WW | Director | 134,387 | $18.55 | $2.49M | $320.1K | 18 | 2023-05-11 |
| WTW | Director | 33,426 | $262.63 | $8.78M | $1.00M | 62 | 2019-04-03 |
| BUFF | Director | 0 | $52.31 | $0 | $0 | 3 | 2018-04-24 |
| Ceres, Inc. (CERE) Delisted | Director | — | $44.96 | — | $0 | 3 | 2014-03-11 |
Recent Filings
124 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-04 | LXRX | Exer (M) | +89,312 | $0 | EDGAR |
| 2026-05-04 | LXRX | Grant (A) | — | $0 | EDGAR |
| 2026-02-27 | LXRX | Buy (P) | +2,000 | $3.0K | EDGAR |
| 2026-02-25 | LXRX | Buy (P) | +100,000 | $147.0K | EDGAR |
| 2026-02-23 | LXRX | Buy (P) | +150,000 | $219.8K | EDGAR |
| 2026-02-18 | LXRX | Buy (P) | +268,497 | $352.9K | EDGAR |
| 2025-06-03 | LXRX | Grant (A) | — | $0 | EDGAR |
| 2025-05-13 | LXRX | Exer (M) | +36,810 | $0 | EDGAR |
| 2024-11-27 | SRRK | Sell (S) | −2,047,165 | -$78.79M | EDGAR |
| 2024-08-05 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Sell (S) | −1,748,820 | -$355.5K | EDGAR |